Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis

• Status: Recruiting
• Trial end date: 2020-07-03
• Target enrollment: 0
• Participant gender: All

Summary

The aim of study was to evaluate the efficacy and safety of Apixaban in patients with acute deep venous thrombosis and active malignancy compared with weight adjusted subcutaneous (LMWH). It was hypothesised that Apixaban could be as effective as rivaroxiban and edoxaban in treatment of patients with acute DVT and active malignancy with a lower risk of bleeding especially in those with GIT cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beni-Suef University
• Treatments: Apixaban; Enoxaparin

Criteria

Inclusion Criteria Patients with active malignancy presenting with acute deep venous thrombosis and still treated with chemotherapy

Exclusion Criteria:

• Patients with pulmonary embolism and hemodynamic instability requiring thrombolytic therapy

• Previous DVT or venous thromboembolism

• Administration of LMWH or unfractionated heparin before randomization

• Brain tumours, cerebral metastes, hepatic tumours or impairment Child-Pugh B or C, -Recent or current active or life threating bleeding (e.g. intr acranial haemorrhage or gastrointestinal bleeding)

• Thrombocytopenia (platelets <100 x 109L)

• Severe chronic kidney disease (estimated glomerular filtration rate <30 ml/minute)

• Pregnant women